Evolent Health

Evolent Health, Inc. engages in the provision of health care delivery and payment services. It deals with population health management, health plan and third party administration, network performance and pharmacy benefit management, risk adjustment, analytics and performance improvement, and technology and electronic medical record integration. The firm operates through Services and True Health segments. The Services segment includes clinical and administrative solutions such as total cost of care management and specialty care management and comprehensive health plan administrative services. The True Health segment offers a physician-led health plan for employer-sponsored health coverage. The company was founded by Frank J. Williams, Seth B. Blackley, and Thomas Peterson III in August 2011 and is headquartered in Arlington, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Evolent Health excels in Q4 2022, eyes growth with Humana

Evolent Health posts strong financials, exceeding revenue and EBITDA targets.
Strategic partnerships and focus on organic growth drive value creation.
Challenges lie in maintaining growth momentum and effective execution.
Opportunities include margin expansion, capital optimization, and Humana partnerships.

Evolent Health surpasses Q1 expectations, eyes revenue growth opportunities

Evolent Health's Q1 performance exceeded expectations, driven by strong revenue growth and margin expansion initiatives. While facing challenges like revenue adjustments and Medicaid rebates, the company remains focused on capitalizing on growth opportunities through strategic partnerships and operational efficiencies.

Evolent Health excels in Q2, eyes $300M EBITDA target

Evolent Health's robust performance in Q2, strategic partnerships, and focus on organic growth position it well to achieve its financial targets.
Challenges lie in Medicaid membership declines, capital allocation optimization, and refinancing decisions amidst market uncertainties.
Opportunities in patient-centric care, CMS changes, and integrated entity approach offer avenues for growth and differentiation in the market.

Evolent Health surpasses Q3 expectations, eyes growth in specialty care

Evolent Health's Q3 performance exceeded expectations, driven by strong revenue growth and profitability, underpinned by strategic partnerships and a unique care model.
Despite challenges in ramping up Performance Suite adoption and maintaining cost control, the company's focus on growth and value creation positions it well for future success.
Opportunities in expanding specialty offerings and leveraging new partnerships highlight Evolent's growth potential and commitment to delivering value in the healthcare sector.

Evolent Health exceeds 2023 targets, eyes growth through partnerships

Evolent Health delivered strong financial results in Q4 2023, surpassing its 2023 targets and setting ambitious goals for 2024, driven by Specialty Care offerings and new revenue agreements.
While facing challenges related to medical utilization and new product launches, the company remains focused on organic growth and profitability, supported by a strategic approach to expansion.
Opportunities in cross-selling, new state expansions, and imaging capabilities position Evolent Health for continued growth and revenue diversification in the healthcare sector.

Evolent Health reports robust Q1 earnings, eyes margin improvements

Evolent Health's Q1 performance showcased strong revenue growth and EBITDA in line with guidance.
The company is optimistic about margin improvements, revenue expansion, and maintaining a balanced pipeline.
Challenges include margin impact from new go-lives and ongoing payer negotiations amid cost pressures.
Opportunities lie in improving gross margins, leveraging population changes, and focusing on cash flow expectations.

Evolent Health reports robust Q2 earnings, eyes growth opportunities ahead

Evolent Health's Q2 2024 earnings call highlighted strong financial performance, strategic initiatives, and a positive outlook for future growth. The company's focus on revenue diversification, margin optimization, and disciplined financial management positions it well for continued success in the evolving healthcare landscape.

Evolent Health revises outlook after Q3 challenges, secures financing

Evolent Health navigated higher medical costs impacting Q3 results, leading to a revised outlook for 2024. Despite challenges in managing expenses and oncology costs, the company remains committed to growth and securing new revenue agreements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Evolent Health, Inc. engages in the provision of healthcare delivery and payment services. It deals with population health management, health plan and third party administration, network performance and pharmacy benefit management, risk adjustment, analytics and performance improvement, and technology and electronic medical record integration. The firm operates through Services and True Health segments. The Services segment includes clinical and administrative solutions such as total cost of care management and specialty care management and comprehensive health plan administrative services. The True Health segment offers a physician-led health plan for employer-sponsored health coverage. The company was founded by Frank J. Williams, Seth B. Blackley, and Thomas Peterson III in August 2011 and is headquartered in Arlington, VA.

Evolent Health, Inc. (NYSE:EVH ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Participants Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Seth Frank - Vice President, Investor Relations Conference Call Participants Charles Rhyee - TD Cowen Jailendra Singh - Truist Securities Jeff Garro - Stephens Stephanie Davis - Barclays Ryan Daniels - William Blair Matthew Gillmor - KeyBanc Kyle Aikman - J.P. Morgan Richard Close - Canaccord Genuity Sean Dodge - RBC Capital Markets Jessica Tassan - Piper Sandler Kevin Caliendo - UBS Daniel Grosslight - Citi David Larsen - BTIG Operator Welcome to the Evolent Earnings Conference Call for the Third Quarter Ended September 30, 2024.

Evolent Health, Inc. (EVH) Q3 2024 Earnings Call Transcript

The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Evolent Health (EVH) Q3 Earnings: A Look at Key Metrics

Pinterest

Redfin

Sweetgreen

U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.2% on Friday.

Sweetgreen Posts Downbeat Results, Joins Evolent Health, Redfin, Pinterest And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Evolent Health (EVH) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.30 per share a year ago.

Evolent Health (EVH) Q3 Earnings and Revenues Lag Estimates

Revenue of $621.4 million, an increase of $110.4 million or 21.6%, from the three months ended September 30, 2023. Net loss attributable to common shareholders of Evolent Health, Inc. of $(31.2) million and a net loss margin of (5.0)%.

Evolent Announces Third Quarter 2024 Results

Beyond analysts' top -and-bottom-line estimates for Evolent Health (EVH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.

Unlocking Q3 Potential of Evolent Health (EVH): Exploring Wall Street Estimates for Key Metrics

Evolent Health (EVH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Evolent Health (EVH) is Poised to Beat Earnings Estimates Again

Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Evolent Health (EVH) Reports Next Week: What to Know Ahead of the Release

Company to Participate in Upcoming Conferences WASHINGTON , Oct. 11, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolent.com.

Evolent To Release Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Shares of Evolent Health Inc (EVH, Financial) fell 3.20% in mid-day trading on Oct 2. The stock reached an intraday low of $25.76, before recovering slightly to $26.19, down from its previous close of $27.05.

Evolent Health Inc (EVH) Stock Price Down 3.2% on Oct 2

Evolent Health is potentially being taken private at a bid of $3.8 billion, offering a 15% upside to the stock at $32 per share. The company's revenue growth rates are expected to decelerate, but potential bidding wars may drive up the stock price further. Evolent's current valuation at 21x forward free cash flow may undervalue the company, potentially leading to higher bids in the future.

Evolent Health: Let The Bidding Begin

Evolent Health is in talks with private equity firms and other companies for a potential sale, in a process that kicked off after the healthcare services provider received inbound interest, people familiar with the matter said on Thursday.

Exclusive: Evolent Health in sale talks after inbound interest, sources say

While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Evolent Health (EVH) Reports Q2 Earnings: What Key Metrics Have to Say

Evolent Health, Inc. (EVH) Q2 2024 Earnings Call Transcript

Evolent Health (EVH) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.14 per share a year ago.

Evolent Health (EVH) Surpasses Q2 Earnings and Revenue Estimates

Revenue of $647.1 million, an increase of $178.0 million or 37.9%, from the three months ended June 30, 2023. Net loss attributable to common shareholders of Evolent Health, Inc. of $(6.4) million and a net loss margin of (1.0)%.

Evolent Announces Second Quarter 2024 Results

Astera Labs Inc

AppFolio

Investors must always balance growth and stability in their portfolios. While employing defensive positions is essential, deploying capital in high-growth sectors like technology can be a formula that accelerates growth.

3 Top Tech Stocks Ready for Robust Gains

Evolent Health (EVH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Evolent Health (EVH) Moves 12.8% Higher: Will This Strength Last?

Company to Participate in Upcoming Conferences WASHINGTON , July 11, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its second quarter 2024 financial results on Thursday, August 8, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolent.com.

Evolent To Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Machinify solution seeks to accelerate the efficiency, quality, and clinical value of Evolent's specialty condition management platform through AI-enabled clinical workflow automation Machinify technology leverages the latest advances in applied machine learning, large language models and data analytics Acquisition expected to benefit health plans, clinicians, and members WASHINGTON , June 4, 2024 /PRNewswire/ -- Evolent Health, Inc. ("Evolent" or "the Company"), (NYSE: EVH) a company focused on achieving better health outcomes for people with complex conditions, today announced it has entered into an agreement to acquire certain assets of Machinify and the exclusive, perpetual and royalty-free license of Machinify Auth, a proven software platform that leverages the latest advances in artificial intelligence to increase the clinical quality, speed and consistency of the clinical reviews for all specialty conditions. Evolent plans to integrate the Machinify Auth team, software applications and AI capabilities into its leading platform.

Evolent signs agreement to acquire artificial intelligence utilization management products and team from Machinify

While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Evolent Health (EVH) Reports Q1 Earnings: What Key Metrics Have to Say

Evolent Health (EVH) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.21 per share a year ago.

Evolent Health (EVH) Q1 Earnings and Revenues Top Estimates

Digital cancer care platform Careology and Evolent (NYSE: EVH) to offer an innovative platform to enable cancer navigation Evolent will embed Careology's digital cancer care technology within its comprehensive care navigation services offered to health plan clients across the U.S. WASHINGTON , May 9, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a $2 billion revenue company focused on achieving better health outcomes for people with complex conditions, today announced it is partnering with Careology , a digital cancer care platform, to enable more coordinated, connected and empowered journeys for people living with cancer in the U.S. Evolent works with more than 70 health plans — spanning approximately 40 million unique members — to improve the quality and affordability of care for cancer and other conditions. The agreement will bring together Careology's "patient-first" digital solution with Evolent's comprehensive care navigation services.

Evolent and Careology form strategic care navigation partnership to enhance cancer care in the U.S.

Revenue of $639.7 million, an increase of $212.0 million or 49.6%, from the three months ended March 31, 2023. Net loss attributable to common shareholders of Evolent Health, Inc. of $(25.2) million and a net loss margin of (3.9)%.

Evolent Announces First Quarter 2024 Results

Company to Participate in Upcoming Conferences WASHINGTON , April 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make healthcare simpler and more affordable, today announced it will release its first quarter 2024 financial results on Thursday, May 9, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolenthealth.com.

News for Evolent Health Stock (EVH)